ENTX Quote, Financials, Valuation and Earnings

Can Fite Biofarma has a net margin of -7192.86% compared to Entera Bio's net margin of --. Entera Bio's return on equity of -113.4% beat Can Fite Biofarma's return on equity of --.

Entera Bio has a consensus price target of --, signalling upside risk potential of 359.77%. On the other hand Can Fite Biofarma has an analysts' consensus of -- which suggests that it could grow by 879.02%. Given that Can Fite Biofarma has higher upside potential than Entera Bio, analysts believe Can Fite Biofarma is more attractive than Entera Bio.

Entera Bio has a beta of 1.548, which suggesting that the stock is 54.802% more volatile than S&P 500. In comparison Can Fite Biofarma has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.764%.

Entera Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can Fite Biofarma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entera Bio pays -- of its earnings as a dividend. Can Fite Biofarma pays out -- of its earnings as a dividend.

Entera Bio quarterly revenues are $42K, which are larger than Can Fite Biofarma quarterly revenues of --. Entera Bio's net income of -$3M is higher than Can Fite Biofarma's net income of --. Notably, Entera Bio's price-to-earnings ratio is -- while Can Fite Biofarma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entera Bio is -- versus 13.42x for Can Fite Biofarma. Usually stocks with elevated PS ratios are considered overvalued.

Compugen has a net margin of -7192.86% compared to Entera Bio's net margin of 7.45%. Entera Bio's return on equity of -113.4% beat Compugen's return on equity of 2.69%.

Entera Bio has a consensus price target of --, signalling upside risk potential of 359.77%. On the other hand Compugen has an analysts' consensus of -- which suggests that it could grow by 150%. Given that Entera Bio has higher upside potential than Compugen, analysts believe Entera Bio is more attractive than Compugen.

Entera Bio has a beta of 1.548, which suggesting that the stock is 54.802% more volatile than S&P 500. In comparison Compugen has a beta of 2.588, suggesting its more volatile than the S&P 500 by 158.818%.

Entera Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entera Bio pays -- of its earnings as a dividend. Compugen pays out -- of its earnings as a dividend.

Entera Bio quarterly revenues are $42K, which are smaller than Compugen quarterly revenues of $17.1M. Entera Bio's net income of -$3M is lower than Compugen's net income of $1.3M. Notably, Entera Bio's price-to-earnings ratio is -- while Compugen's PE ratio is 53.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entera Bio is -- versus 2.39x for Compugen. Usually stocks with elevated PS ratios are considered overvalued.

BiomX has a net margin of -7192.86% compared to Entera Bio's net margin of --. Entera Bio's return on equity of -113.4% beat BiomX's return on equity of --.

Entera Bio has a consensus price target of --, signalling upside risk potential of 359.77%. On the other hand BiomX has an analysts' consensus of -- which suggests that it could grow by 1187.48%. Given that BiomX has higher upside potential than Entera Bio, analysts believe BiomX is more attractive than Entera Bio.

Entera Bio has a beta of 1.548, which suggesting that the stock is 54.802% more volatile than S&P 500. In comparison BiomX has a beta of 1.314, suggesting its more volatile than the S&P 500 by 31.404%.

Entera Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entera Bio pays -- of its earnings as a dividend. BiomX pays out -- of its earnings as a dividend.

Entera Bio quarterly revenues are $42K, which are larger than BiomX quarterly revenues of --. Entera Bio's net income of -$3M is lower than BiomX's net income of $9.6M. Notably, Entera Bio's price-to-earnings ratio is -- while BiomX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entera Bio is -- versus -- for BiomX. Usually stocks with elevated PS ratios are considered overvalued.

Pluri has a net margin of -7192.86% compared to Entera Bio's net margin of -1804.3%. Entera Bio's return on equity of -113.4% beat Pluri's return on equity of -438.78%.

Entera Bio has a consensus price target of --, signalling upside risk potential of 359.77%. On the other hand Pluri has an analysts' consensus of -- which suggests that it could grow by 619.1%. Given that Pluri has higher upside potential than Entera Bio, analysts believe Pluri is more attractive than Entera Bio.

Entera Bio has a beta of 1.548, which suggesting that the stock is 54.802% more volatile than S&P 500. In comparison Pluri has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.245%.

Entera Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entera Bio pays -- of its earnings as a dividend. Pluri pays out -- of its earnings as a dividend.

Entera Bio quarterly revenues are $42K, which are smaller than Pluri quarterly revenues of $326K. Entera Bio's net income of -$3M is higher than Pluri's net income of -$5.9M. Notably, Entera Bio's price-to-earnings ratio is -- while Pluri's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entera Bio is -- versus 39.53x for Pluri. Usually stocks with elevated PS ratios are considered overvalued.